GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs ... to further assess and allow comparison of several GLP-1RA agents' impact on steady-state ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist ... study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA versus ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

investigating the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on the incidence of atrial fibrillation (AF) following hospitalisation for heart failure (HF) were released.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.